Program - 5th Pituitary Congress
Sunday June 28, 1998 - Tuesday June 30, 1998

Session 1:  
**Plenary Session**  
*Moderators:* Giovanni Faglia and Steven Lamberts

4:15 - 5:00  
PM  
Development of the pituitary  
Kathy Mahon

5:00 - 5:45  
Neuroendocrinological actions and implications of leptin  
Felipe Casanueva

6:00 - 9:00  
Poster session and Reception

MONDAY

Session 2:  
**New insight into pituitary disease provided by genetic disruption**  
*Moderators:* Hiroshi Demura and Larry Jameson

8:00 - 8:30  
AM  
Pit 1 and prop 1 phenotypes - clinical aspects  
R. Pfaffle

8:30 - 9:00  
Dopamine D2 Receptor knockout mice  
Malcolm Low

9:00 - 9:30  
Transgenic models to elucidate the roles of inhibin and activin in reproduction, oncogenesis and development.  
Martin Matzuk

10:00 - 10:30  
Coffee Break

Session 3:  
**Advances in Prolactinomas**  
*Moderators:* Gaetano Lombardi and Peter Snyder

10:30 - 11:00  
AM  
New therapies of prolactinomas  
Jonathan Webster

11:00 - 11:30  
Recurrent and resistant prolactinomas  
Mary Lee Vance

11:30 - 12:00  
Pregnancy and prolactinomas  
Mark Molitch

12:00 - 2:00  
Luncheon Seminars

Session 4:  
**Genetics of Pituitary Tumors**  
*Moderators:* Julian Davis and Ana Spada

2:00 - 2:30  
Molecular mechanisms of pituitary oncogenesis: an overview
PM
2:30 - 3:00  Menin: the story unfolds  
Allen Spiegel

3:00 - 3:30  Methylation mechanisms in pituitary tumorigenesis  
William Farrell, Ph.D.

3:30 - 4:00  Coffee Break

**Session 5:**  The growth hormone neuroendocrine axis - new developments  
*Moderators:* Gloria S Tannenbaum and Michael Thorner

4:00 - 4:30  Hypothalamic networks involved in the control of GH secretion  
Iain CAF Robinson

4:30 - 5:00  Somatostatin receptor subtypes: functions and regulation  
Agnes Schonbrunn

5:00 - 5:30  Growth hormone releasing peptides  
Roy Smith

5:30 - 6:00  Pituitary Society Business Meeting & Awards  
Presentation by (get name from Mary Lee and David)

6:00 - 6:30  Presidential Address (get name from Mary Lee)

Evening free

**TUESDAY**

**Session 6:**  Plenary Session  
*Moderators:* Iain Clarke and Patricia Hinkle

7:45 - 8:30  Mechanistic and functional insights derived from pituitary cell strains in culture  
Armen H. Tashjian Jr.

**Session 7:**  Novel actions of pituitary hormones  
*Moderators:* Charles Clevenger and Karin Eidne

8:30 - 9:00  Actions of the growth hormone/prolactin family of proteins in the placenta  
Daniel Linzer

9:00 - 9:30  Growth hormone and IGF effects on bone  
Anne Klibanski

9:30 - 10:00  Effect of pituitary hormones on mammary tissue  
David Kleinberg

10:00 - 10:30  Coffee Break

**Session 8:**  Hot Topics  
*Moderators:* Robert Gagel and Agnes Schonbrunn

10:30 - 10:45  Different retinoid compounds suppress TSHbeta promoter activity in vitro and the thyrotrope-restricted isoform RXRy1 appears to mediate this effect  
Bryan Haugen
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:00</td>
<td>Pituitary-Thyroid axis alterations during use of an RXR-selective retinoid analog</td>
<td>Steven I. Sherman</td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Identification and functional characterization of an intermediate isoform of the human prolactin receptor</td>
<td>Charles V. Clevenger</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>A pituitary adenoma in a family with a mutant calcium-sensing receptor. A role of this mutant receptor in pituitary oncogenesis?</td>
<td>Ana O. Hoff</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>Targeted ablation of gonadotrophs in transgenic mice affects early development of lactotrophs</td>
<td>Hugo Vankelecom, University of Leuven, Belgium</td>
</tr>
<tr>
<td>11:45 - 12:00</td>
<td>POMC and Somatostatin knockout mice: clinically relevant phenotypes</td>
<td>Ute Hochgeschwender</td>
</tr>
<tr>
<td>12:00 - 12:15</td>
<td>Progesterone binds to the oxytocin receptor and inhibits receptor signalling: A novel non-genomic steroid action</td>
<td>Hans H. Zingg</td>
</tr>
<tr>
<td>12:15 - 12:30</td>
<td>A Phase I study of a novel vasopressin receptor antagonist, VPA-985, a potential therapeutic agent for vasopressin-mediated hypnoatremia</td>
<td>Gayle P. Orczyk</td>
</tr>
<tr>
<td>12:30 - 2:30</td>
<td>Luncheon Seminars</td>
<td></td>
</tr>
<tr>
<td>2:30 - 3:00</td>
<td>Pituitary specific estrogen receptors</td>
<td>Margaret A. Shupnik</td>
</tr>
<tr>
<td>3:00 - 3:30</td>
<td>Paracrine interactions in pituitary cell function</td>
<td>Gwen Childs</td>
</tr>
<tr>
<td>3:30 - 4:00</td>
<td>Model Pituitary Cell lines from Transgenic Mice</td>
<td>Nira Ben-Jonathan</td>
</tr>
<tr>
<td>4:00 - 4:30</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>4:30 - 5:00</td>
<td>The evolving field of growth hormone antagonists: Basic Studies</td>
<td>John Kopchick</td>
</tr>
<tr>
<td>5:00 - 5:30</td>
<td>Pathophysiology of dominant negative growth hormone mutations</td>
<td>Priscilla Dannies</td>
</tr>
<tr>
<td>5:30 - 6:00</td>
<td>Clinical studies with growth hormone antagonists</td>
<td>David Clemmons</td>
</tr>
<tr>
<td>6:00 - 6:30</td>
<td>Metabolic basis of adult growth hormone replacement</td>
<td>Jens Otto Jorgensen</td>
</tr>
<tr>
<td>6:30</td>
<td>Closing remarks</td>
<td></td>
</tr>
</tbody>
</table>
Luncheon Seminars (80 min)
All sessions to run concurrently on Monday and Tuesday

1. Management of difficult pituitary cases
   Moderator: Ivor Jackson
   Panel: Ian McCutcheon, David M. Cook
           Akira Shimatzu, Sylvia Asa
           Brooke Swearingen, Paolo Beck-Peccoz
           Lynette Kaye Nieman
   Cases to be presented by panel members

2. Clinical uses of CRH and management of Cushing's Syndrome
   Moderator: James Findling
   Speakers: George Chrousos
             Beverly Biller
             Xavier Bertagna

3. Uses of pituitary irradiation in management of pituitary tumors
   Moderator: Kalmon Post
   Edward Laws: Gamma knife
   Jay Loeffler: Fractionated conformal radiotherapy
   Ariel Barkan: Conventional radiation in the treatment of acromegaly

4. Somatostatin and growth hormone releasing peptides: clinical uses
   Moderator: Michael Sheppard
   Steven Lamberts: Somatostatin receptor mediated radio and chemotherapy
   Phillipe Jaquet: Lanreotide vs. Sandostatin LAR
   Ezio Ghigo: Growth hormone releasing peptides

5. Genetic testing
   Moderator: Maria Louisa Brandi
   Ashley Grossman: The clinical use of genetic information in the management of pituitary tumors and other endocrine tumor syndromes
   Sunita K. Agarwal: Dideoxy fingerprinting for detection of mutations in the MEN1 gene
   Mark Hughes: Single cell diagnostics

6. New molecular strategies
   Moderator: Nancy Cooke
   Rob Burgess: Novel knockout strategies for mouse mutagenesis
   Pamela Mellon: Targeted Oncogenesis in Transgenic Mice
   William Chin: Strategies for the identification of new trans-acting factors
7. **Longterm complications of GH treatment**  
*Moderator:* Richard Robbins  

**Panel:**  
- Charles Sklar  
- Steve Shalet  
- Bengt-Ake Bengtsson  
  
8. **Novel or controversial therapeutic uses of GH**  
*Moderator:* Marcello Delano Bronstein  

**Panel:**  
- G. Michael Besser  
- David N. Herndon  
- Vivien Herman-Bonert  
  
- Oncological risk in children and adults treated with growth hormone  
- Growth Hormone Replacement in Adults  
- Treatment of burn patients  
- GH impact on cardiovascular function